生脉胶囊联合盐酸埃克替尼片对晚期非小细胞肺癌患者靶向治疗的临床疗效

Clinical efficacy of Shengmai capsule combined with icotinib hydrochloride tablets in the targeted treatment of advanced non-small cell lung cancer

目的探讨生脉胶囊联合盐酸埃克替尼片对晚期非小细胞肺癌患者靶向治疗的临床疗效。方法收集2016年1月至2018年1月期间收治的晚期非小细胞肺癌患者94例,按照随机数字表法分为对照组与观察组,各47例。对照组患者予盐酸埃克替尼片125 mg,po,tid;观察组在对照组基础上予生脉胶囊0.9 g,po,tid。2组疗程均为8周。评估或测量治疗前后生存质量、肿瘤标志物(癌胚抗原CEA和糖类抗原CA125)水平、不良反应、中位无进展生存期(PFS)和临床疗效。结果治疗后,观察组总有效率高于对照组(74.46%vs 53.19%,P<0.05),血清CEA和CA125水平低于对照组(P<0.05),不良反应发生率低于对照组(14.89%vs 42.55%,P<0.05),中位PFS长于对照组[(10.32±1.87)月vs(7.43±1.28)月,P<0.05]。结论生脉胶囊联合盐酸埃克替尼片对晚期非小细胞肺癌患者靶向治疗近期疗效良好,且可延长患者无进展生存期。

AIM To investigate the clinical efficacy of the Shengmai capsule combined with icotinib hydrochloride tablets in the targeted treatment of advanced non-small cell lung cancer.METHODS The 94 patients with advanced non-small cell lung cancer admitted from January 2016 to January 2018 were divided into control group(n=47)and observation group(n=47)according to random number table method.The control group was treated with the icotinib hydrochloride tablets(125 mg,po,tid),while the observation group was treated with Shengmai capsule(0.9 g,po,tid)on the basis of the control group.The course of treatment in both groups was 8 weeks.The therapeutic effects,adverse drug reactions and median progression free survival(PFS)were compared between the 2 groups,and the changes of quality of life and tumor markers were compared before and after treatment.RESULTS The total effective rate of the observation group was higher than that of the control group(74.46%vs 53.19%,P<0.05).The levels of serum carcinoembryonic antigen(CEA)and carbohydrate antigen 125(CA125)in the observation group were lower than those in the control group before treatment(P<0.05).The adverse drug reaction rate in the observation group was lower than that in the control group(14.89%vs 42.55%,P<0.05).PFS in the observation group was longer than that in the control group[(10.32±1.87)mon vs(7.43±1.28)mon,P<0.05].CONCLUSION Shengmai capsule combined with icotinib hydrochloride tablets has a good short-term therapeutic effect on advanced non-small cell lung cancer patients,and can prolong the progression-free survival of patients.